Biogen Message Board - Msg: 5820725

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 167.63

+1.8%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Hong-Lee Yu who wrote (746)	9/23/1998 12:57:00 PM
From: Harold Engstrom	Read Replies (1) of 1686

Hong-Lee Yu, Biogen continues to match or exceed their stated goals. Currently, there are more patients on Avonex than many analysts ever expected, and growth is apparently accelerating. It would not be surprising if there were not 50K patients on Avonex by the end of this calendar year. If so, Avonex revenues will exceed the most agressive analysts estimates handily for next year. Note that a launch into the secondary progressive market is also possible late next year, and that should nearly double the market for Avonex. Add LFA3TIP and 5C8 and CVT124 and VLA4 results and then we will see a further explosion of interest in owning this company. That said, $70/share seems pretty reasonable right now.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next